Tony Hill to head up meningitis test developer HiberGene
This article was originally published in Clinica
Irish firm HiberGene Diagnostics, which is developing rapid molecular diagnostic tests for meningitis, has appointed Tony Hill CEO. Mr Hill was most recently global sales director at Belgian diagnostics company Innogenetics, which became part of Fujirebio when the Japanese group bought it from Abbott in 2010 (www.clinica.co.uk, 24 September 2010). Before this, he was vice-president at OraSure Technologies (Bethlehem, Pennsylvania), which focuses on oral fluid tests for conditions such as HIV and hepatitis. Dublin-based HiberGene, founded in 2009, is developing two tests, using its novel amplification platform, for the most common forms of meningitis: one to detect Meningococcus; and the other to pinpoint Pneumococcal meningitis. They can provide results in under 40 minutes; conventional culturing methods can take several weeks. The firm is currently looking for funding to progress these diagnostics through to commercialisation, and develop new infectious disease tests.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.